ALCEDIAG is an innovative diagnostic company specializing in the development and commercialization of blood tests, monitoring solutions, and companion diagnostics, primarily for mental health. These offerings are based upon the company’s distinctive expertise in epigenetics, RNA, and Artificial Intelligence, complemented by neurosciences and psychiatry.

ALCEDIAG’s unique approach is protected by seven patent families and supported by a global network of Key Opinion Leaders, who serve both as advocate for and early adopt of ALCEDIAG’s solutions.

ALCEDIAG ambition is to harness the unexplored power of RNA, Artifical Intelligence combined to neurosciences to bring innovative solutions that will change the lives of millions of patients.

“At ALCEDIAG, our ambition is to be at the forefront of mental health diagnosis, aspiring to pioneer advancements in the field. We firmly believe that our scientific and technological innovations will play a pivotal role in ushering in a new era for mental health—powered by precision medicine and biology.

This paradigm shift is poised to bring about a significant enhancement in patient management, ultimately yielding substantial impacts on patient outcomes and the overall quality of life for both individuals and their loved ones. We are dedicated to leveraging cutting-edge science and technology to contribute to the transformative landscape of mental health, fostering a future where precision and biology converge for the betterment of individuals and society as a whole.”

ALCEDIAG team comprises women and men with diverse backgrounds—molecular biologists, neuroscientists, bioinformaticians, psychiatrists, and business experts—all working together. We welcome talented individuals who share a passion for advancing science and contributing to people’s wellbeing. This diversity is our strength and our gateway to innovation.